Jason Bednar
Stock Analyst at Piper Sandler
(2.06)
# 3,020
Out of 4,967 analysts
182
Total ratings
36.96%
Success rate
-5.65%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Overweight | $105 → $83 | $65.33 | +27.05% | 14 | Aug 28, 2025 | |
| ICUI ICU Medical | Initiates: Overweight | $145 | $126.93 | +14.24% | 1 | Aug 15, 2025 | |
| SOLV Solventum | Maintains: Overweight | $87 → $94 | $71.82 | +30.88% | 7 | Aug 8, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $185 → $200 | $188.15 | +6.30% | 10 | Aug 8, 2025 | |
| MASI Masimo | Maintains: Overweight | $200 → $210 | $137.67 | +52.54% | 16 | Aug 6, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $19 | $20.72 | -8.30% | 13 | Aug 1, 2025 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $110 → $105 | $90.68 | +15.79% | 13 | Jul 31, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $250 → $190 | $137.16 | +38.52% | 31 | Jul 31, 2025 | |
| LUNG Pulmonx | Downgrades: Neutral | $9 → $2.5 | $1.73 | +44.51% | 12 | Jul 31, 2025 | |
| NVCR NovoCure | Reiterates: Overweight | $34 | $12.19 | +178.92% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4.5 → $3.5 | $4.12 | -15.05% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $13.81 | +15.86% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $68.39 | +12.59% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $16.16 | -19.55% | 2 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $2.76 | +63.04% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $242.02 | +9.50% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $3.59 | +67.13% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.48 | +101.15% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $2.21 | +804.98% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $469.07 | -20.69% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $71.60 | +32.68% | 1 | Apr 19, 2023 |
The Cooper Companies
Aug 28, 2025
Maintains: Overweight
Price Target: $105 → $83
Current: $65.33
Upside: +27.05%
ICU Medical
Aug 15, 2025
Initiates: Overweight
Price Target: $145
Current: $126.93
Upside: +14.24%
Solventum
Aug 8, 2025
Maintains: Overweight
Price Target: $87 → $94
Current: $71.82
Upside: +30.88%
Becton, Dickinson and Company
Aug 8, 2025
Maintains: Neutral
Price Target: $185 → $200
Current: $188.15
Upside: +6.30%
Masimo
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $137.67
Upside: +52.54%
Envista Holdings
Aug 1, 2025
Maintains: Neutral
Price Target: $17 → $19
Current: $20.72
Upside: -8.30%
Merit Medical Systems
Jul 31, 2025
Maintains: Overweight
Price Target: $110 → $105
Current: $90.68
Upside: +15.79%
Align Technology
Jul 31, 2025
Maintains: Overweight
Price Target: $250 → $190
Current: $137.16
Upside: +38.52%
Pulmonx
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.73
Upside: +44.51%
NovoCure
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.19
Upside: +178.92%
May 8, 2025
Maintains: Neutral
Price Target: $4.5 → $3.5
Current: $4.12
Upside: -15.05%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $13.81
Upside: +15.86%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $68.39
Upside: +12.59%
Apr 23, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $16.16
Upside: -19.55%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.76
Upside: +63.04%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $242.02
Upside: +9.50%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $3.59
Upside: +67.13%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.48
Upside: +101.15%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $2.21
Upside: +804.98%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $469.07
Upside: -20.69%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $71.60
Upside: +32.68%